|
A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness
Jie Liu, Shuang Li, Fan Yang, Tianyu Li, Rui Li, Yousuf Waheed, Chen Meng, Shulin Li, Kun Liu, Yanshan Tong, Haisheng Xu, Chuankuo Tian, Xinglei Zhou
Received November 27, 2023 Accepted February 20, 2024 Published online April 23, 2024
Background/Aims: Roxadustat, an oral medication for treating renal anemia, is a hypoxia-inducible factor prolyl hydroxylase inhibitor used for regulating iron metabolism and promoting erythropoiesis. To investigate the efficacy and safety of roxadustat in patients undergoing peritoneal dialysis (PD)..
|
